DNM1P30

Across TCGA pan-cancer cohorts, DNM1P30 RNA is linked to patient survival in 7 of 34 cancer types, making it the most broadly survival-associated DNM1P30 data layer compared with 1 for mutation status.

The strongest signal is observed in stomach adenocarcinoma (STAD), where higher DNM1P30 RNA is associated with worse disease-free survival. In most high-consensus cancer types, elevated DNM1P30 expression acts as an unfavorable survival marker.

STAD, KIRP, and THCA are the cancer types where DNM1P30 RNA most reproducibly stratifies survival.

RNA survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
STAD	DFS	Tertile	All	0.188	0.385	.005	126	view →
KIRP	OS	Tertile	II,III,IV	0.127	0.859	<.001	93	view →
THCA	DFS	Tertile	All	0.496	0.833	<.001	81	view →
READ	OS	Tertile	All	0.164	0.660	<.001	63	view →
DLBC	DFS	Tertile	II,III,IV	0.022	0.837	<.001	36	view →
LUSC	DFS	Tertile	II,III,IV	0.135	0.663	.015	18	view →
LGG	OS	Tertile	All	0.743	0.891	.044	3	view →

Pink = unfavorable, green = favorable. Showing the 7 strongest of 7 lineages.

DNM1P30–STAD (DFS)

Open the STAD breakdown →